obesity

News

Novo Nordisk's IL-6 drug flunks two more heart trials

Novo Nordisk has opted to discontinue two late-stage trials of IL-6 inhibitor ziltivekimab in heart failure, after taking an interim look at the data.

News

Roche’s Genentech strikes $2.3bn deal for Hanmi obesity drug...

Roche’s Genentech has agreed a deal worth up to $2.3 billion to develop and sell Hanmi Pharmaceutical’s experimental obesity drug HM17321.

News

UK MHRA authorises orforglipron private prescription

Eli Lilly has announced that orforglipron (Foundayo) is now available to be prescribed for eligible adults via private prescription.

R&D

GLP-1 RAs in CKM management: A Q&A with CORXEL

GLP-1 RA medicine has transformed treatment of metabolic diseases such as obesity and diabetes. We spoke with China's CORXEL about theirs.

News

Lilly sues over 'illegal sales' of obesity drug retatrutide

Eli Lilly has sued six US-based companies it accuses of participating in an illegal black market for experimental weight-loss drug retatrutide.

News

UK is first European country to approve Lilly's Foundayo

Eli Lilly's oral GLP-1 agonist Foundayo has been approved for weight management and type 2 diabetes in the UK, its first European market.

Novo Nordisk's IL-6 drug flunks two more heart trials

Roche’s Genentech strikes $2.3bn deal for Hanmi obesity drug...

UK MHRA authorises orforglipron private prescription

GLP-1 RAs in CKM management: A Q&A with CORXEL

Lilly sues over 'illegal sales' of obesity drug retatrutide

UK is first European country to approve Lilly's Foundayo

Lily gets FDA nod for SERD-CDK 4/6 combo in breast cancer

Discover a new era of healthcare panel engagement: Grounded ...

obesity

Editor's Picks